Northrop Grumman delivered strong Q4 2025 performance, with revenue up 10% year-over-year, higher operating income, and a record backlog of $95.7 billion.

Northrop Grumman delivered a strong Q3 2025, with $10.42B in revenue and $7.67 EPS. The company showed robust operational performance, expanded margins, and secured a $1.8B missile defense contract, contributing to a book-to-bill ratio of 1.17x.

Northrop Grumman delivered strong Q2 2025 results with revenue growth, higher operating income, and a significant EPS increase driven by the Training Services divestiture and solid performance across most segments.

Northrop Grumman's Q1 2025 results showed a revenue decline and significantly lower EPS due to a one-time B-21 adjustment. However, the company maintains a record backlog and reaffirmed full-year sales guidance, highlighting strong demand in defense.

Northrop Grumman reported fourth-quarter sales of $10.7 billion, comparable to the prior year. Net earnings totaled $1.3 billion, or $8.66 per diluted share. The company's backlog reached a new record of $91.5 billion.

Northrop Grumman reported a 2% increase in sales to $10.0 billion for Q3 2024 compared to $9.8 billion in Q3 2023. Net earnings increased to $1.0 billion, or $7.00 per diluted share, from $937 million, or $6.18 per diluted share, in the same period last year. The company also raised its 2024 segment operating income and MTM-adjusted EPS guidance.

Northrop Grumman reported a 7% increase in sales, reaching $10.2 billion, and a 19% increase in diluted earnings per share to $6.36. The company also raised its 2024 sales guidance to $41.0 - $41.4 billion and MTM-adjusted EPS guidance to $24.90 - $25.30.

Northrop Grumman reported a strong first quarter in 2024, with sales increasing by 9% to $10.1 billion and diluted earnings per share rising by 15% to $6.32. The company's performance was driven by continued strong demand and improved operating margins, leading to a reaffirmed 2024 company-level guidance.

Northrop Grumman's Q4 2023 sales increased by 6% to $10.6 billion, driven by strong demand across its sectors. However, the company reported a net loss of $535 million, or $3.54 per diluted share, due to a $1.56 billion pre-tax charge related to the B-21 program. Despite the net loss, the total backlog reached a record $84.2 billion.

Northrop Grumman reported a strong third quarter in 2023, with sales increasing by 9% to $9.8 billion and net earnings rising to $937 million, or $6.18 per diluted share. The company's backlog reached a record $84 billion, and it raised its 2023 sales guidance by $400 million to approximately $39 billion.

Northrop Grumman reported a 9% increase in sales, reaching $9.6 billion, driven by strong global demand, improved supply chain deliveries, and successful talent acquisition. Diluted earnings per share were $5.34. The company increased its full-year sales guidance by $400 million, indicating a positive outlook.

Northrop Grumman reported a 6% increase in sales to $9.3 billion and a 6% increase in operating income to $947 million for the first quarter of 2023. Diluted earnings per share were $5.50. The company reaffirmed its 2023 guidance for sales, operating income, and adjusted free cash flow.

Northrop Grumman reported strong Q4 2022 results, with sales increasing by 16% to $10.0 billion. Diluted EPS was $13.46, including a $5.96 per share MTM benefit, and transaction-adjusted EPS increased 25% to $7.50. The company's performance was driven by strong demand, the timing of material receipts, and continued improvement in labor availability trends. The company is raising its sales outlook for 2023 and expects to deliver strong multi-year cash flow growth.

Northrop Grumman reported a 3% increase in sales to $9.0 billion for Q3 2022 compared to $8.7 billion in Q3 2021. Diluted EPS was $5.89, which included a $0.18 unfavorable impact from marketable securities. The company reaffirmed its 2022 guidance for sales, EPS, and transaction-adjusted free cash flow.

Northrop Grumman reported second quarter 2022 sales of $8.8 billion, a decrease compared to $9.2 billion in the second quarter of 2021. Net earnings totaled $946 million, or $6.06 per diluted share, compared to $1.0 billion, or $6.42 per diluted share, in the second quarter of 2021. The company reaffirmed its full year guidance.

Northrop Grumman reported first quarter 2022 sales of $8.8 billion, a decrease compared to $9.2 billion in the first quarter of 2021. Net earnings totaled $955 million, or $6.10 per diluted share, compared to $2.2 billion, or $13.43 per diluted share, in the first quarter of 2021. The company's performance was in line with expectations, and recent global geopolitical events underscore the relevance of their capabilities.

Northrop Grumman reported fourth quarter 2021 sales of $8.6 billion. Fourth quarter 2021 net earnings increased to $2.7 billion including a $1.8 billion after-tax mark-to-market pension and OPB (“MTM”) benefit. Fourth quarter 2021 transaction-adjusted net earnings were $948 million, or $6.00 per diluted share, and include an after-tax charge of $73 million, or $0.46 per diluted share, on the F-35 program at Aeronautics Systems largely driven by COVID-19-related impacts.

Northrop Grumman reported a decrease in sales by 4% to $8.7 billion, but organic sales increased by 3%. Net earnings increased by 8% to $1.1 billion, or $6.63 per diluted share. The company raised its full year earnings guidance and continues to expect strong organic sales growth.

Northrop Grumman reported a 3% increase in sales to $9.2 billion and a 3% increase in net earnings to $1.04 billion, or $6.42 per diluted share, compared to the second quarter of 2020. The company raised its 2021 sales guidance to $35.8 billion to $36.2 billion and transaction-adjusted EPS guidance to $24.40 to $24.80.

Northrop Grumman reported a 6% increase in sales to $9.2 billion and a significant rise in EPS to $13.43. Excluding the benefit from the IT services sale, transaction-adjusted EPS increased by 28% to $6.57. The company also raised its 2021 sales guidance to $35.3 to $35.7 billion and transaction-adjusted EPS guidance to $24.00 to $24.50.

Northrop Grumman reported a strong fourth quarter and full-year 2020, with Q4 sales increasing 17% to $10.2 billion and full-year sales increasing 9% to $36.8 billion. The company's Q4 EPS was $1.97, with an MTM-adjusted EPS of $6.59. The company's total backlog increased to $81.0 billion.

Northrop Grumman reported a 7% increase in sales to $9.1 billion and a 6% increase in net earnings to $1.0 billion for Q3 2020. The company raised its 2020 guidance, expecting sales of $35.7 to $36 billion and free cash flow of $3.3 to $3.6 billion. New awards totaled $20.3 billion, resulting in a record backlog of $81.3 billion.

Northrop Grumman reported a 5% increase in sales, reaching $8.9 billion, and a 17% increase in net earnings, amounting to $1.0 billion, or $6.01 per diluted share. The company also raised its 2020 guidance, expecting sales between $35.3 and $35.6 billion and free cash flow between $3.15 and $3.55 billion.

Northrop Grumman reported a 5% increase in sales to $8.6 billion and a 2% increase in EPS to $5.15. Net awards totaled $7.9 billion and the company updated its 2020 sales and MTM-adjusted EPS guidance for expected COVID-19 related impacts, while free cash flow guidance remained unchanged.

Northrop Grumman reported a 7% increase in sales to $8.7 billion for the fourth quarter of 2019. The company experienced a net loss of $409 million due to a $1.4 billion after-tax mark-to-market (MTM) expense. However, MTM-adjusted net earnings increased 12% to $949 million, or $5.61 per share. The total backlog increased by 21% to $64.8 billion.